Nasonex 0.05% nasal spray 120 doses

Tradename

Nasonex

Nasonex

Compound:

One dose contains:

mometasone furoate (micronized, in the form of monohydrate) 50 mcg

Auxiliary components:

dispersed cellulose (microcrystalline cellulose treated with sodium carmellose), glycerol, citric acid monohydrate, sodium citrate dihydrate, polysorbate 80, benzalkonium chloride (in the form of a 50% solution), purified water.

Properties

GCS for local use. It has anti-inflammatory and anti-allergic effects when used in doses that do not cause systemic effects.

Inhibits the release of inflammatory mediators. It increases the production of lipomodulin, which is an inhibitor of phospholipase A, which leads to a decrease in the release of arachidonic acid and, accordingly, inhibition of the synthesis of metabolic products of arachidonic acid — cyclic endoperoxides, prostaglandins. It prevents the marginal accumulation of neutrophils, which reduces inflammatory exudate and production of lymphokines, inhibits the migration of macrophages, and leads to a decrease in the processes of infiltration and granulation. Reduces inflammation by reducing the formation of chemotaxis substance (influence on late allergy reactions), inhibits the development of an immediate allergic reaction (due to inhibition of the production of arachidonic acid metabolites and a decrease in the release of inflammatory mediators from mast cells).

Indications

— seasonal and year-round allergic rhinitis in adults, adolescents and children from 2 years of age;

— acute sinusitis or exacerbation of chronic sinusitis in adults (including the elderly) and adolescents from 12 years of age — as an auxiliary therapeutic agent in antibiotic treatment;

— acute rhinosinusitis with mild to moderate symptoms without signs of severe bacterial infection in patients aged 12 years and older;

Dosage and administration

Adults (including elderly patients) and adolescents from 12 years of age. The recommended preventive and therapeutic dose of the drug is 2 inhalations (50 mcg each) in each nostril 1 time / day. Upon reaching the therapeutic effect for maintenance therapy, it is possible to reduce the dose to 1 inhalation in each nostril 1 time / day

If a reduction in the symptoms of the disease cannot be achieved by using the drug at the recommended therapeutic dose, the daily dose can be increased to 4 inhalations in each nostril 1 time / day (total daily dose — 400 mcg). After reducing the symptoms of the disease, a dose reduction is recommended.

The onset of action of the drug is usually noted clinically within 12 hours after the first use of the drug.

Contraindications

— hypersensitivity to the components of the drug;

— recent surgery or trauma of the nose with damage to the mucous membrane of the nasal cavity — before the wound heals (due to the inhibitory effect of GCS on the healing process);

-childhood and adolescence (with seasonal and year-round allergic rhinitis — up to 2 years, with acute sinusitis or exacerbation of chronic sinusitis — up to 12 years, with polyposis — up to 18 years) — due to the lack of relevant data.

Side effects

Nosebleeds, as well as discharge of blood-stained mucus or blood clots), burning sensation in the nose, irritation of the nasal mucosa, ulceration of the nasal mucosa.

Irritation of the pharynx (feeling of irritation of the mucous membrane of the pharynx).

Storage method: